- Home
- ACAD vs ATS Comparison
ACAD vs ATS Comparison
Compare ACAD & ATS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ATS
- Stock Information
- Founded
- ACAD 1993
- ATS 1978
- Country
- ACAD United States
- ATS Canada
- Employees
- ACAD N/A
- ATS N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ATS
- Sector
- ACAD Health Care
- ATS
- Exchange
- ACAD Nasdaq
- ATS Nasdaq
- Market Cap
- ACAD 2.5B
- ATS 2.3B
- IPO Year
- ACAD 2004
- ATS 2023
- Fundamental
- Price
- ACAD $17.44
- ATS $25.77
- Analyst Decision
- ACAD Buy
- ATS Sell
- Analyst Count
- ACAD 15
- ATS 2
- Target Price
- ACAD $24.21
- ATS $30.50
- AVG Volume (30 Days)
- ACAD 1.8M
- ATS 109.0K
- Earning Date
- ACAD 05-07-2025
- ATS 01-01-0001
- Dividend Yield
- ACAD N/A
- ATS N/A
- EPS Growth
- ACAD N/A
- ATS N/A
- EPS
- ACAD 1.37
- ATS 0.63
- Revenue
- ACAD $996,283,000.00
- ATS $1,908,353,570.00
- Revenue This Year
- ACAD $13.07
- ATS N/A
- Revenue Next Year
- ACAD $10.06
- ATS $13.22
- P/E Ratio
- ACAD $12.74
- ATS $40.72
- Revenue Growth
- ACAD 22.42
- ATS N/A
- 52 Week Low
- ACAD $13.40
- ATS $20.90
- 52 Week High
- ACAD $20.68
- ATS $35.42
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- ATS 53.81
- Support Level
- ACAD $14.45
- ATS $25.15
- Resistance Level
- ACAD $15.31
- ATS $25.90
- Average True Range (ATR)
- ACAD 0.69
- ATS 0.72
- MACD
- ACAD 0.37
- ATS 0.17
- Stochastic Oscillator
- ACAD 94.92
- ATS 84.29
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ATS ATS Corporation
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.